FindTrial
Sign In

ANV419

DRUG4 trials

Sponsors

Vall D Hebron Institute Of Oncology, Anaveon AG

Conditions

Adult DiseaseAdvanced Solid TumorAdvanced selected solid tumors: melanomaCutaneous MelanomaHematologic DiseasesLung CancerMelanoma (Skin)Metastatic Melanoma

Phase 1

A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.
CompletedNCT04855929
Anaveon AGAdult Disease, Advanced Solid Tumor, Lung Cancer
Start: 2021-05-25End: 2024-07-18Updated: 2024-11-08
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
CompletedNCT05578872
Anaveon AGAdult Disease, Advanced Solid Tumor, Cutaneous Melanoma +2
Start: 2022-12-16End: 2024-08-01Updated: 2025-08-26
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
TerminatedNCT05641324
Anaveon AGAdult Disease, Hematologic Diseases, Multiple Myeloma +2
Start: 2023-02-10End: 2023-07-12Updated: 2024-02-12

Phase 2

Phase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419) vs High dose IL2 after Tumor Infiltrating Lymphocytes (TIL) Therapy in patients with melanoma, NSCLC and cervical cancer. The PragmaTIL
RecruitingCTIS2023-506400-99-00
Vall D Hebron Institute Of OncologyAdvanced selected solid tumors: melanoma, non-small cell lung cancer (NSCLC) and cervical cancer.
Start: 2025-01-15Target: 24Updated: 2025-12-02

Related Papers

Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
Journal for ImmunoTherapy of Cancer2023-11-0116 citations
OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti-PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma.
Journal of Clinical Oncology2023-06-01
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.
Journal of Clinical Oncology2023-06-01
631 Phase I dose escalation study in patients with advanced solid tumors with ANV419, a novel fusion protein selective for IL-2Rβ/γ
Regular and Young Investigator Award Abstracts2022-11-01
A phase I/II study of ANV419, a selective IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, in patients with advanced solid tumors.
Journal of Clinical Oncology2022-06-015 citations